Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CBRS is drawing attention amid a steep post-IPO selloff, with traders pointing to TD Cowens price-target cut, shares becoming eligible for sale through IPO lockups, and reported insider selling as sources of pressure. Bears question its valuation, ability to scale, and reliance on OpenAI, while some investors view the decline as overdone and are adding shares for the long term.

Robinhoods steep selloff ahead of its quarterly earnings has traders debating whether the decline reflects its premium valuation and analyst caution or broader market and crypto weakness. Some see the pullback as a buying opportunity, while others expect further downside and point to recent analyst downgrades and a price-target cut.

DJT is drawing attention amid a steep decline toward record lows, with many traders questioning its business fundamentals and viewing it as a sentiment-driven Trump proxy. Bearish posts link the outlook to political backlash and the midterms, while a smaller group sees the selloff as a buying opportunity; no specific company announcement dominates.

Morgan Stanleys top-pick designation and more optimistic AWS growth outlook are driving attention, with traders linking the upgrade to Amazons sharp rally and its AI-cloud prospects. Many are bullish, while others question whether the move will hold and are watching for earnings to confirm the outlook.

Oklos steep decline is being discussed alongside share dilution from its ATM offering and reported insider sales, with traders also questioning the companys pre-revenue status and long commercialization timeline. Some see the selloff and high short interest as a potential rebound setup, while others expect continued pressure amid dilution and weakness across speculative nuclear stocks.

Disc Medicine is surging after its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints in erythropoietic protoporphyria, strengthening the case for an FDA resubmission after an earlier rejection. Traders are debating the trial-driven rally against dilution concerns from a proposed stock offering, with some expecting further gains and others anticipating selling pressure.

AGNCs third-quarter results, especially the sharp decline in tangible book value and a GAAP loss, have intensified its selloff. Traders are divided between buying the high-yield shares and worrying that rate and mortgage-spread pressures, leverage, and weaker book value could threaten the dividend.

Pre-earnings positioning is driving attention, with traders focused on GE Aerospaces Q3 report and what it may signal about engine demand, supply constraints, margins, and guidance. Views are split between dip buyers citing the companys backlog and demand and cautious traders pointing to the recent weakness and downside hedging.

CFO Raju Prasads resignation and immediate replacement by longtime finance executive Andrew Silver are drawing attention, with traders debating the timing while noting the filing reported no disagreement over financial matters. The discussion also centers on upcoming CTX310 Phase 1b data and a zugo-cel update as near-term pipeline catalysts.

CoreWeaves steep selloff has centered on concerns about its heavy debt burden, financing costs and the sustainability of its capital-intensive AI infrastructure expansion amid a broader sector pullback. Traders are split: some view the shares as oversold with rebound potential, while others fear dilution or default risk, and the Goldman Sachs upgrade has not resolved the debate.